Fujifilm Diosynth to invest $1.6 billion to enhance cell culture manufacturing services

Japanese contract development and manufacturing organization (CDMO). Fujifilm Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, has announced the investment of $1.6 billion to enhance and expand its cell culture manufacturing services. This investment will enhance Fujifilm Diosynth’s sites in Hillerød, Denmark, and Texas in the USA.

As part of this investment, Fujifilm Diosynth is further expanding its capacity to support large-scale cGMP fed batch production by adding 8 x 20,000L bioreactors and two downstream processing streams in its Hillerød, Denmark facility. The additional production capacity will make the Hillerød facility the largest end-to-end CDMO in Europe, offering a total of 20 x 20,000L bioreactors for drug substance production complemented by comprehensive drug product and finished goods services. The investment is expected to create approximately 450 jobs.

This investment will also expand cell culture manufacturing solutions at the Texas site. Fujifilm Diosynth will implement its proprietary SymphonX production equipment, enabling cGMP MaruX continuous processing at the single-use cell culture manufacturing site.